Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | PPIB | P23284 | 1/20 | 0.40 |
| ▸ | PPIA | P62937 | 1/20 | 0.40 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
| ▸ | PPIG | Q13427 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27637035 | 0.98 | EPHX2 (0.45) | EPHX2TSHRTDP1GFERALDH1A1 | |
| SCHEMBL5839383 | 0.88 | LTA4H (0.46) | ALDH1A1CYP3A4LOXL2HTTCA2 | |
| SCHEMBL19050970 | 0.82 | ESR1 (0.52) | EPHX2ALDH1A1HTTCA2LTA4H | |
| SCHEMBL8058539 | 0.82 | TPSAB1 (0.45) | TSHRLOXL2HTTCA2LTA4H | |
| SCHEMBL18392595 | 0.81 | EPHX2 (0.42) | EPHX2TSHRTDP1GFERALDH1A1 | |
| SCHEMBL22507923 | 0.81 | EPHX2 (0.42) | EPHX2TSHRTDP1GFERALDH1A1 | |
| SCHEMBL22887096 | 0.79 | LTA4H (0.41) | ALDH1A1HTTCA2LTA4H | |
| SCHEMBL3440203 | 0.79 | LOXL2 (0.50) | EPHX2CYP3A4LOXL2HTTCA2 | |
| SCHEMBL8040670 | 0.79 | CHRM2 (0.47) | ALDH1A1HTTLTA4H | |
| SCHEMBL15961525 | 0.79 | LMNA (0.48) | ALDH1A1HTTCA2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091565-A1 | NSD2-TARGETED CHEMICAL DEGRADERS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-05-25 | — | — | WO | disclosed |
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200317635-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-10669253-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10464925-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190071415-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-9914740-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-13 | — | — | US | disclosed |
| US-9914740-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170014523-A1 | SPLICEOSTATIN ANALOGS AND METHOS FOR THEIR PREPARATION | PFIZER (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170014523-A1 | SPLICEOSTATIN ANALOGS AND METHOS FOR THEIR PREPARATION | PFIZER (US) | 2017-01-19 | — | — | US | disclosed |
| US-9504669-B2 | Spliceostatin analogs and methods for their preparation | PFIZER INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160022626-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER (US) | 2016-01-28 | — | — | US | disclosed |
| US-9169264-B2 | Spliceostatin analogs and methods for their preparation | PFIZER INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-1313732-B1 | OXINDOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| EP-1313732-A1 | OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002020524-A1 | OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022626-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | SF3B5, SNRPA1, SF3B1 | EPHX2 3793/4885TSHR 2101/4885TDP1 2250/4885 |
| US-20190071415-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | EPHX2 2741/4885TSHR 3028/4885TDP1 3319/4885 |
| US-20160152628-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | EPHX2 2227/4885TSHR 2274/4885TDP1 134/4885 |
| US-11059801-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, XIAP, MDM2 | EPHX2 2903/4885TSHR 3312/4885TDP1 3884/4885 |
| US-10464925-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | EPHX2 2741/4885TSHR 3028/4885TDP1 3319/4885 |
| US-20140134193-A1 | SPLICEOSTATIN ANALOGS AND METHODS FOR THEIR PREPARATION | SF3B5, SNRPA1, SF3B1 | EPHX2 3793/4885TSHR 2101/4885TDP1 2250/4885 |
| US-20170014523-A1 | SPLICEOSTATIN ANALOGS AND METHOS FOR THEIR PREPARATION | SF3B5, SF3B1, SNRPA1 | EPHX2 4076/4885TSHR 947/4885TDP1 2487/4885 |
| US-10669253-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, SMARCE1, MDM2 | EPHX2 1831/4885TSHR 3723/4885TDP1 3145/4885 |
| US-20200317635-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | EPHX2 2741/4885TSHR 3028/4885TDP1 3319/4885 |
| US-20180134684-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | EPHX2 2741/4885TSHR 3028/4885TDP1 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.